135 related articles for article (PubMed ID: 23118328)
1. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Cabaleiro T; Román M; Ochoa D; Talegón M; Prieto-Pérez R; Wojnicz A; López-Rodríguez R; Novalbos J; Abad-Santos F
Drug Metab Dispos; 2013 Jan; 41(1):224-9. PubMed ID: 23118328
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.
Prieto-Pérez R; Ochoa D; Cabaleiro T; Román M; Sánchez-Rojas SD; Talegón M; Abad-Santos F
J Clin Pharmacol; 2013 Dec; 53(12):1261-7. PubMed ID: 23996211
[TBL] [Abstract][Full Text] [Related]
4. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.
Ochoa D; Prieto-Pérez R; Román M; Talegón M; Rivas A; Galicia I; Abad-Santos F; Cabaleiro T
Pharmacogenomics; 2015; 16(9):939-48. PubMed ID: 26122864
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
7. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.
Martínez C; García-Martín E; Blanco G; Gamito FJ; Ladero JM; Agúndez JA
Br J Clin Pharmacol; 2005 Jan; 59(1):62-9. PubMed ID: 15606441
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
[TBL] [Abstract][Full Text] [Related]
9. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding.
Blanco G; Martínez C; Ladero JM; Garcia-Martin E; Taxonera C; Gamito FG; Diaz-Rubio M; Agundez JA
Pharmacogenet Genomics; 2008 Jan; 18(1):37-43. PubMed ID: 18216720
[TBL] [Abstract][Full Text] [Related]
10. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes.
Karaźniewicz-Łada M; Luczak M; Główka F
Xenobiotica; 2009 Jun; 39(6):476-85. PubMed ID: 19480553
[TBL] [Abstract][Full Text] [Related]
13. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender.
Dorado P; Beltrán LJ; Machín E; Peñas-Lledó EM; Terán E; Llerena A;
Pharmacogenomics; 2012 Nov; 13(15):1711-7. PubMed ID: 23171336
[TBL] [Abstract][Full Text] [Related]
14. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
[TBL] [Abstract][Full Text] [Related]
15. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
16. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.
Sachse-Seeboth C; Pfeil J; Sehrt D; Meineke I; Tzvetkov M; Bruns E; Poser W; Vormfelde SV; Brockmöller J
Clin Pharmacol Ther; 2009 Mar; 85(3):273-6. PubMed ID: 19005461
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.
Donner KM; Hiltunen TP; Suonsyrjä T; Hannila-Handelberg T; Tikkanen I; Antikainen M; Hirvonen A; Kontula K
J Hypertens; 2009 Oct; 27(10):2001-9. PubMed ID: 19593208
[TBL] [Abstract][Full Text] [Related]
18. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort.
Haschke-Becher E; Kirchheiner J; Trummer O; Grünbacher G; Kainz A; Boehm BO; März W; Renner W
Pharmacogenomics; 2010 Oct; 11(10):1359-65. PubMed ID: 21047199
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.
López-Rodríguez R; Novalbos J; Gallego-Sandín S; Román-Martínez M; Torrado J; Gisbert JP; Abad-Santos F
Pharmacol Res; 2008 Jul; 58(1):77-84. PubMed ID: 18694831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
